Figure 4.

CAL-101 treatment improves tumor control by human chimeric antigen receptor (CAR) T cells compared to vehicle and AKTi treatment. (A) Individual tumor curves of NSG mice given M108 subcutaneously 51 days prior were treated with 4 × 10⁵ CD3⁺ mesoCAR T cells primed with vehicle, AKTi, or CAL-101; n = 8–12 mice/group in one experiment. (B) Tumor weight at day 71 posttransfer. (C) Percent change in size of tumors 71 days posttreatment compared to baseline tumor measurement at time of treatment. (D) Frequency of human CD45⁺ lymphocytes within the blood of treated mice 55 days posttransfer; n = 2–12 mice/group from one experiment. One-way repeated measures ANOVA; ns, not statistically significant, *p < 0.05. (E) Frequency of CD62L⁺ or TIM3⁺CD3⁺ tumor infiltrating lymphocyte (TIL) from lung carcinoma after 5 weeks of growth with either 2 weeks of CAL-101 treatment or not, and (F) change in frequencies of CD62L⁺ or TIM3⁺CD3⁺ TIL during drug treatment with CAL-101 or without (vehicle) from week 3 to week 5 of ex vivo culture. Groups compared by Student’s t-test, *p < 0.05.